Does Network Health Cover Dupixent?

What Is Dupixent and Why Is It Prescribed?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines that drive type 2 inflammatory conditions. The FDA has granted it six distinct approvals across dermatology, pulmonology, and gastroenterology. Because it targets a shared receptor rather than a single cytokine, dupilumab affects multiple downstream inflammatory pathways simultaneously. [1]

FDA-Approved Indications

The FDA first approved dupilumab in March 2017 for moderate-to-severe atopic dermatitis in adults inadequately controlled on topical therapies. Subsequent approvals followed for: add-on maintenance therapy in moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma (2018); chronic rhinosinusitis with nasal polyposis (2019); eosinophilic esophagitis in patients aged 12 and older (2022); prurigo nodularis (2022); and uncontrolled COPD with type 2 inflammation (2024). [2]

Each indication carries its own prior authorization criteria. An insurer reviewing a dupilumab request for atopic dermatitis will apply different step-therapy benchmarks than one reviewing a request for EoE.

Clinical Evidence Supporting Use

The SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that dupilumab 300 mg every two weeks produced an IGA 0/1 response (clear or almost clear skin) in approximately 37% of adults with moderate-to-severe atopic dermatitis at 16 weeks, versus roughly 9% for placebo (P<0.001). [3]

The LIBERTY ASTHMA QUEST trial (N=1,902) showed dupilumab reduced severe exacerbation rates by 47.7% in patients with baseline blood eosinophils of 300 cells/mcL or more compared to placebo. [4]

These trial results directly inform the "medically necessary" criteria most insurers, including Network Health, embed in their coverage policies.

How Network Health's Formulary and Prior Authorization Process Works

Network Health is a regional Wisconsin health insurer serving individual, employer-sponsored, and Medicare Advantage members primarily in northeastern Wisconsin. Its formulary decisions follow a pharmacy and therapeutics (P&T) committee review cycle, and specialty biologics like dupilumab are almost universally placed on high-cost specialty tiers requiring prior authorization (PA). [5]

Formulary Tier Placement

Dupixent typically lands on Network Health's specialty tier, sometimes called Tier 4 or Tier 5 depending on the specific plan year and product line. Specialty-tier drugs carry the highest cost-sharing percentages, sometimes 20% to 33% coinsurance with plan-specific caps. Reviewing the Summary of Benefits and Coverage (SBC) document for your specific Network Health plan year is the most reliable way to confirm the current tier assignment.

The Affordable Care Act requires insurers to cover essential health benefits and prohibits discriminatory benefit design, but it does not prohibit tiered cost-sharing for specialty drugs. [6] That means a drug can be "covered" yet still carry substantial out-of-pocket cost before manufacturer assistance or a secondary payer is applied.

Prior Authorization Criteria Network Health Typically Applies

PA criteria for dupilumab in atopic dermatitis at most commercial insurers, including regional plans like Network Health, generally require: [7]

• A confirmed diagnosis of moderate-to-severe atopic dermatitis by a board-certified dermatologist or allergist
• Documentation that topical corticosteroids (TCS) and at least one calcineurin inhibitor or crisaborole have been tried and failed or are contraindicated
• Documented failure of at least one conventional systemic agent (most commonly cyclosporine, methotrexate, or azathioprine) unless clinically contraindicated
• Prescriber attestation that the patient is 6 months of age or older and meets FDA labeling criteria
• A baseline severity assessment using a validated tool such as the Eczema Area and Severity Index (EASI) or Investigator Global Assessment (IGA) score of 3 or 4

For asthma indications, PA usually requires spirometry confirming airflow obstruction, an eosinophil count of at least 150 to 300 cells/mcL or oral corticosteroid dependence, and documented inadequate control on medium-to-high dose inhaled corticosteroid plus a long-acting beta-agonist (ICS/LABA). [8]

Step Therapy: What It Means in Practice

Step therapy requires patients to try and fail less expensive therapies before a payer approves a biologic. For atopic dermatitis, this typically means at least one systemic immunosuppressant must be documented. The American Academy of Dermatology's 2023 atopic dermatitis guidelines acknowledge that conventional systemic agents carry significant toxicity profiles, which clinicians should document when requesting a step-therapy override. [9]

Wisconsin enacted step therapy reform legislation that mirrors the 2018 federal step-therapy protections extended to insured plans. Under these protections, a step-therapy override must be granted if: the required therapy is contraindicated, the patient already failed the required therapy, or the required therapy will cause or is likely to cause an adverse reaction. Documenting any of these exceptions in the PA submission dramatically improves approval odds.

How to Submit a Prior Authorization for Dupixent Through Network Health

The PA process involves the prescribing clinician's office, not the patient directly. However, patients who understand the process can advocate more effectively.

Step 1: Gather Clinical Documentation

Before submitting, the prescribing office should compile: [10]

• Office visit notes confirming diagnosis and severity
• Pharmacy records or chart notes documenting prior treatment trials and dates of failure
• Lab results (for asthma: CBC with differential showing eosinophil counts; for AD: no specific lab is required but photographic documentation of lesion extent helps)
• A completed PA request form specific to Network Health's specialty pharmacy or PBM

Step 2: Submit Through Network Health's Designated Channel

Network Health uses a pharmacy benefits manager (PBM) for specialty drug processing. PA requests for Dupixent should be submitted through the PBM's portal or by fax using Network Health's specialty drug PA form, available on the member or provider portal at networkhealth.com. Under Wisconsin Administrative Code Ins 18, commercial health insurers must acknowledge receipt and respond to non-urgent PA requests within three business days. [11]

Step 3: Await the Decision

If approved, the PA is typically valid for 12 months, after which a renewal PA must be submitted with documentation of treatment response. If denied, the denial letter must include the specific clinical reason and instructions for appeal.

What to Do If Network Health Denies Dupixent Coverage

Denials happen. The denial rate for specialty biologics on first submission across commercial payers runs roughly 20% to 30%, according to data tracked by specialty pharmacy benefit managers. Understanding the appeals ladder is essential.

Internal Appeal

File a written internal appeal within the timeframe specified in the denial letter (typically 180 days for commercial plans). The appeal should include: [12]

• A letter of medical necessity from the prescribing physician citing specific clinical findings
• Published guidelines supporting dupilumab use (the AAD 2023 AD guidelines [9] and the GINA 2024 asthma report [13] are primary sources)
• Peer-reviewed evidence, such as the SOLO trials [3] or QUEST trial [4], demonstrating clinical benefit
• Documentation of all prior therapies tried, doses used, and reasons for discontinuation

The American Academy of Dermatology's position statement on access to biologic therapy directly supports medical necessity letters. Citing the AAD's statement that "biologic therapy represents standard of care for patients with moderate-to-severe atopic dermatitis who have failed conventional systemic therapy" can strengthen an appeal.

External Review

If the internal appeal is denied, Wisconsin law entitles members to an independent external review by an accredited review organization. External review decisions in Wisconsin are binding on the insurer. Request external review within four months of an internal appeal denial. The Wisconsin Office of the Commissioner of Insurance (OCI) oversees this process. [14]

Peer-to-Peer Review

Before or during the internal appeal, request a peer-to-peer (P2P) review. This is a phone call between the prescribing physician and the insurer's medical director. Published data from specialty pharmacy benefit analyses suggest that P2P review overturns initial denials in approximately 40% to 60% of cases for biologic drugs. [15] The prescribing dermatologist or allergist should lead this call, not office staff.

Dupixent Cost and Patient Assistance Options

Even with coverage, out-of-pocket costs can be significant.

List Price and Insured Cost-Sharing

Dupixent's current U.S. List price is approximately $3,700 per month for the 300 mg every-two-weeks dosing regimen used in atopic dermatitis. After insurer negotiation, the net cost is lower, but specialty-tier coinsurance can still leave patients paying hundreds of dollars per fill.

Dupixent MyWay Copay Card

Sanofi and Regeneron offer the Dupixent MyWay copay assistance program for eligible commercially insured patients. Qualifying patients may pay as little as $0 per month, with a maximum benefit of up to $13,000 per year. The program is not available to patients on federal or state government insurance (Medicare, Medicaid, Tricare). [16] Enrollment is completed online at dupixent.com/myway or by calling 1-844-DUPIXENT.

Patient Assistance Program

Patients without insurance or who are ineligible for the copay card may qualify for the Dupixent Patient Assistance Program (PAP), which provides the drug at no cost based on income and insurance status. Income thresholds and eligibility criteria are reviewed annually.

Network Health Medicare Advantage and Dupixent

Network Health offers Medicare Advantage plans in Wisconsin. Medicare Part D formularies operate under different rules than commercial plans. The Centers for Medicare and Medicaid Services (CMS) requires Part D plans to include at least two drugs in each therapeutic category, but biologics for atopic dermatitis may not always appear on a given plan's formulary in a given year.

Medicare Advantage enrollees should request a formulary exception if dupilumab is not on their plan's formulary, or is on a tier that makes it unaffordable. Under CMS rules, a formulary exception requires the prescriber to document that all covered alternatives are not clinically appropriate for the specific patient. [17]

The Inflation Reduction Act of 2022 capped Medicare Part D out-of-pocket drug spending at $2,000 per year beginning in 2025, which may reduce the financial burden for Medicare Advantage members approved for Dupixent. [18]

Qualifying for Dupixent Under Medicare

Medicare coverage for dupilumab in atopic dermatitis generally mirrors commercial PA criteria: documented moderate-to-severe disease and prior treatment failure. For asthma under Medicare, pulmonary function testing records and eosinophil lab values are usually required in the PA package.

Renewal PA and Ongoing Coverage Maintenance

Approval is not permanent. Network Health's PA for dupilumab typically lasts 12 months. Renewal requires documentation of: [19]

• Continued diagnosis and medical necessity
• Treatment response measured against baseline (e.g., reduction in EASI score by at least 50%, or IGA improvement)
• Absence of disqualifying adverse events

If response documentation is incomplete at renewal, the PA may lapse, causing a pharmacy fill rejection. The prescribing office should schedule a renewal-documentation visit at month 10 to allow time for submission before the PA expiration date.

What Dermatologists and Allergists Recommend When Seeking Coverage

Board-certified dermatologists treating patients with moderate-to-severe atopic dermatitis consistently document severity using validated scoring tools from the first visit onward, precisely because those scores become evidence in future PA submissions and appeals. [20]

The National Eczema Association recommends that patients request copies of all PA submissions and denial letters, keep a symptom and treatment diary, and request itemized explanation of benefits (EOB) statements after each fill to track cost-sharing against plan-year deductible and out-of-pocket maximum accumulation. [21]

Prescribers who submit PA forms without complete step-therapy documentation account for a large share of initial denials that are later overturned on appeal. Thorough documentation at the initial submission stage, rather than at the appeal stage, reduces delays in patient access by weeks.

How Dupixent Compares to Other Covered Options Network Health May Require First

Network Health's PA criteria may list specific agents the plan prefers to try before dupilumab. Knowing these helps patients and prescribers document failures accurately. [22]

Topical Therapies

• Topical corticosteroids (TCS): hydrocortisone, triamcinolone, clobetasol
• Topical calcineurin inhibitors: tacrolimus ointment (Protopic), pimecrolimus cream (Elidel)
• PDE4 inhibitor: crisaborole (Eucrisa), ruxolitinib cream (Opzelura)

Conventional Systemics (Step Therapy Agents)

• Cyclosporine: used off-label for atopic dermatitis in the U.S.; typically 3 to 6 months of trial documented
• Methotrexate: off-label; requires CBC and LFT monitoring
• Azathioprine: off-label; requires TPMT enzyme testing before initiation
• Mycophenolate mofetil: off-label; used in refractory cases

The AAD's 2023 guidelines assign a moderate recommendation to cyclosporine for moderate-to-severe AD and acknowledge that methotrexate and azathioprine have lower evidence quality but remain widely used in practice. [9] Documenting not just failure but specific adverse effects (e.g., cyclosporine-induced nephrotoxicity or hypertension) strengthens a step-therapy override request.

Newer Biologics and JAK Inhibitors That May Also Require PA

Tralokinumab (Adbry), lebrikizumab (Ebglyss), and the JAK inhibitors abrocitinib (Cibinqo) and upadacitinib (Rinvoq) have received FDA approvals for moderate-to-severe atopic dermatitis. Network Health's formulary may prefer one of these over dupilumab in certain patient subgroups, or may require failure of one oral JAK inhibitor before approving a biologic. JAK inhibitor use carries a boxed warning for serious infections, malignancy, thrombosis, and cardiovascular events, which clinicians can cite when requesting dupilumab instead of a JAK inhibitor for appropriate patients. [23]

Practical Action Checklist for Network Health Members Seeking Dupixent

Patients navigating this process benefit from a clear sequence of steps rather than a general overview.

1. Confirm your Network Health plan's formulary tier for dupilumab by logging into your member portal or calling the number on your insurance card.
2. Ask your dermatologist or allergist to initiate the PA using Network Health's current PA form and to attach all step-therapy documentation at the time of initial submission.
3. Enroll in Dupixent MyWay before or at the time of first fill, even if your PA is still pending.
4. If denied, request the denial reason in writing and ask your prescriber to schedule a peer-to-peer review within 10 business days.
5. File a written internal appeal with a letter of medical necessity, guideline citations, and trial evidence if the P2P review does not resolve the denial.
6. Request external review through the Wisconsin OCI if the internal appeal fails.
7. Document renewal visit data starting at month 10 of the initial PA period.